Summit logo.png
Summit Therapeutics set to join Russell 3000® Index
June 08, 2021 07:00 ET | Summit Therapeutics Inc.
Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual...
Summit logo.png
Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
June 03, 2021 08:00 ET | Summit Therapeutics Inc.
Cambridge, MA, June 03, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) invites our shareholders and other interested parties to attend our Company’s Annual Shareholders’ Meeting,...
Summit Master_rgb_png.png
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021
May 17, 2021 08:00 ET | Summit Therapeutics Inc.
Cambridge, MA, May 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021....
Summit Master_rgb_png.png
Summit Therapeutics Announces Closing of $75 Million Rights Offering
May 12, 2021 14:59 ET | Summit Therapeutics Inc.
Cambridge, MA, May 12, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results. The rights offering...
Summit Master_rgb_png.png
Summit Therapeutics Publishes Scientific Updates to Corporate Website
May 06, 2021 08:00 ET | Summit Therapeutics Inc.
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our...
Summit Master_rgb_png.png
Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering
May 05, 2021 12:47 ET | Summit Therapeutics Inc.
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight...
Summit Master_rgb_png.png
Summit Therapeutics Announces Commencement of Rights Offering
April 21, 2021 08:04 ET | Summit Therapeutics Inc.
Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Summit Therapeutics Announces Commencement of Rights Offering Cambridge, MA, April 21, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today...
Summit Master_rgb_png.png
Summit Therapeutics Announces Rights Offering
March 26, 2021 07:00 ET | Summit Therapeutics Inc.
Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the...
DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020
November 12, 2020 12:30 ET | Deinove
DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020       ·Yannick Pletan to present the DNV3837 mechanism of action, key features of the antibiotic candidate and the...
Summit Master_rgb_png.png
Summit Announces Results of Court Meeting and General Meeting
August 19, 2020 16:01 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces Results of Court Meeting and General Meeting Oxford, UK, and Cambridge, MA, US, August 19, 2020 – Summit Therapeutics plc...